Business
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization o
About this update from Ultragenyx Pharmaceutical Inc.
[{"type":"image","alt":"Ultragenyx Pharmaceutical Inc.","displaySize":"","headline":null,"caption":"Ultragenyx Pharmaceutical Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":113,"url":"https://media.zenfs.com/en/globenewswire.com/98c2a760a19e68caceb0f8447079e784"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WFxQplTkxt9FOMPM4ARqBw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/98c2a760a19e68caceb0f8447079e784","width":300,"height":113}},"lazy":false},{"type":"text","content":"Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome","length":333,"tagName":"p"},{"type":"text","content":"NOVATO, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported preliminary unaudited 2025 revenue results, cash and investments at year end 2025, and provided a corporate update.","length":373,"tagName":"p"},{"type":"text","content":"“In 2025, we delivered another year of significant revenue growth, with preliminary revenue exceeding the top end of guidance," said Emil Kakkis, chief executive officer and president of Ultragenyx. "The year ahead will be transformational for our company and the rare disease communities we serve, with two potential gene therapy approvals of first-ever treatments, and a pivotal data readout from our Phase 3 program in Angelman syndrome, setting the stage for our next phase of growth."","length":504,"tagName":"p"},{"type":"text","content":"Financial Update2025 Preliminary Revenue (unaudited) Total revenue for 2025 is estimated to be $672 million to $674 million, which exceeds the top end of the guidance range, and represents approximately 20% growth versus 2024. Crysvita® revenue for 2025 is estimated to be $480 million to $482 million, which exceeds the top end of the guidance range, and represents approximately 17% growth versus 2024. Dojolvi® revenue for 2025 is estimated ...